Concepts (248)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 67 | 2024 | 176 | 21.090 |
Why?
|
| Polymyxin B | 19 | 2024 | 28 | 7.880 |
Why?
|
| Microbial Sensitivity Tests | 37 | 2024 | 96 | 6.080 |
Why?
|
| Acinetobacter baumannii | 8 | 2024 | 12 | 5.210 |
Why?
|
| Cephalosporins | 12 | 2024 | 13 | 4.770 |
Why?
|
| Pseudomonas Infections | 10 | 2023 | 18 | 4.460 |
Why?
|
| Acinetobacter Infections | 6 | 2024 | 8 | 4.190 |
Why?
|
| Klebsiella pneumoniae | 10 | 2022 | 12 | 4.120 |
Why?
|
| Humans | 61 | 2024 | 4936 | 3.110 |
Why?
|
| Bacteremia | 6 | 2022 | 10 | 3.000 |
Why?
|
| beta-Lactamase Inhibitors | 8 | 2023 | 10 | 2.990 |
Why?
|
| Minocycline | 5 | 2022 | 5 | 2.840 |
Why?
|
| Pseudomonas aeruginosa | 9 | 2023 | 34 | 2.820 |
Why?
|
| Ceftazidime | 6 | 2024 | 9 | 2.780 |
Why?
|
| beta-Lactamases | 11 | 2023 | 12 | 2.560 |
Why?
|
| Carbapenems | 4 | 2024 | 7 | 2.530 |
Why?
|
| Klebsiella Infections | 6 | 2022 | 7 | 2.520 |
Why?
|
| Acute Kidney Injury | 5 | 2024 | 14 | 2.400 |
Why?
|
| Kidney | 9 | 2023 | 51 | 2.040 |
Why?
|
| Azabicyclo Compounds | 6 | 2024 | 7 | 2.000 |
Why?
|
| Female | 33 | 2024 | 2523 | 1.960 |
Why?
|
| Tandem Mass Spectrometry | 10 | 2024 | 66 | 1.950 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 11 | 2024 | 12 | 1.940 |
Why?
|
| Animals | 26 | 2024 | 1711 | 1.910 |
Why?
|
| Amikacin | 4 | 2023 | 7 | 1.690 |
Why?
|
| Drug Resistance, Bacterial | 4 | 2017 | 16 | 1.650 |
Why?
|
| Male | 28 | 2024 | 2491 | 1.640 |
Why?
|
| Drug Combinations | 7 | 2024 | 25 | 1.590 |
Why?
|
| Sepsis | 3 | 2023 | 4 | 1.570 |
Why?
|
| Polymyxins | 3 | 2023 | 5 | 1.520 |
Why?
|
| Aminoglycosides | 5 | 2023 | 17 | 1.520 |
Why?
|
| Bacterial Proteins | 6 | 2022 | 56 | 1.490 |
Why?
|
| Middle Aged | 18 | 2024 | 967 | 1.460 |
Why?
|
| Kidney Tubules, Proximal | 4 | 2024 | 27 | 1.430 |
Why?
|
| beta-Lactams | 5 | 2020 | 12 | 1.400 |
Why?
|
| Chromatography, Liquid | 6 | 2020 | 37 | 1.370 |
Why?
|
| beta-Lactam Resistance | 4 | 2019 | 6 | 1.340 |
Why?
|
| Anti-Infective Agents | 4 | 2022 | 15 | 1.340 |
Why?
|
| Bacterial Infections | 4 | 2019 | 6 | 1.320 |
Why?
|
| Aged | 16 | 2024 | 703 | 1.280 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2023 | 125 | 1.210 |
Why?
|
| Colistin | 4 | 2019 | 4 | 1.190 |
Why?
|
| Ceftriaxone | 3 | 2020 | 4 | 1.110 |
Why?
|
| Vancomycin | 3 | 2020 | 28 | 1.110 |
Why?
|
| Low Density Lipoprotein Receptor-Related Protein-2 | 3 | 2024 | 7 | 1.070 |
Why?
|
| Mice | 11 | 2024 | 685 | 1.000 |
Why?
|
| Creatinine | 7 | 2023 | 8 | 0.980 |
Why?
|
| Rats | 10 | 2023 | 241 | 0.980 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 2 | 0.960 |
Why?
|
| Pneumonia, Bacterial | 3 | 2015 | 5 | 0.950 |
Why?
|
| Gram-Negative Bacterial Infections | 5 | 2019 | 5 | 0.930 |
Why?
|
| Adult | 14 | 2024 | 1567 | 0.890 |
Why?
|
| Cerebral Ventriculitis | 1 | 2024 | 1 | 0.890 |
Why?
|
| Lung | 4 | 2018 | 35 | 0.870 |
Why?
|
| Licensure, Pharmacy | 1 | 2024 | 7 | 0.860 |
Why?
|
| Culture Media | 1 | 2024 | 18 | 0.850 |
Why?
|
| Iron | 1 | 2024 | 10 | 0.840 |
Why?
|
| Epithelial Cells | 2 | 2014 | 31 | 0.840 |
Why?
|
| Apoptosis | 1 | 2024 | 46 | 0.830 |
Why?
|
| Educational Measurement | 1 | 2024 | 49 | 0.830 |
Why?
|
| Pharmacists | 1 | 2024 | 41 | 0.830 |
Why?
|
| Pharmaceutical Preparations | 2 | 2021 | 12 | 0.820 |
Why?
|
| Moths | 1 | 2023 | 2 | 0.780 |
Why?
|
| Students, Pharmacy | 1 | 2024 | 73 | 0.770 |
Why?
|
| Education, Pharmacy | 1 | 2024 | 73 | 0.770 |
Why?
|
| Retrospective Studies | 8 | 2024 | 341 | 0.750 |
Why?
|
| Bacteria | 2 | 2021 | 47 | 0.740 |
Why?
|
| Imipenem | 2 | 2012 | 3 | 0.740 |
Why?
|
| Cystic Fibrosis | 1 | 2021 | 6 | 0.720 |
Why?
|
| Gram-Negative Bacteria | 4 | 2023 | 7 | 0.700 |
Why?
|
| Aged, 80 and over | 8 | 2018 | 262 | 0.690 |
Why?
|
| Disease Models, Animal | 7 | 2020 | 225 | 0.680 |
Why?
|
| HIV Infections | 1 | 2023 | 104 | 0.680 |
Why?
|
| Lactams | 1 | 2021 | 2 | 0.680 |
Why?
|
| Transitional Care | 1 | 2020 | 1 | 0.680 |
Why?
|
| Treatment Outcome | 7 | 2018 | 177 | 0.660 |
Why?
|
| Pneumonia | 2 | 2017 | 20 | 0.620 |
Why?
|
| Staphylococcus aureus | 3 | 2024 | 20 | 0.620 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 26 | 0.610 |
Why?
|
| Texas | 4 | 2024 | 190 | 0.570 |
Why?
|
| Administration, Intravenous | 5 | 2022 | 9 | 0.570 |
Why?
|
| Models, Statistical | 3 | 2014 | 62 | 0.570 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 5 | 0.560 |
Why?
|
| Immunity, Innate | 1 | 2018 | 8 | 0.560 |
Why?
|
| Urinary Tract Infections | 2 | 2016 | 5 | 0.550 |
Why?
|
| Prospective Studies | 6 | 2018 | 111 | 0.550 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2017 | 1 | 0.540 |
Why?
|
| Transcription Factors | 1 | 2018 | 66 | 0.530 |
Why?
|
| Blood Proteins | 1 | 2017 | 1 | 0.530 |
Why?
|
| Neutropenia | 1 | 2017 | 2 | 0.520 |
Why?
|
| Escherichia coli | 1 | 2019 | 111 | 0.520 |
Why?
|
| Outpatients | 2 | 2014 | 11 | 0.520 |
Why?
|
| Models, Biological | 1 | 2018 | 124 | 0.500 |
Why?
|
| Antimicrobial Stewardship | 1 | 2016 | 3 | 0.490 |
Why?
|
| Plasma | 2 | 2015 | 6 | 0.480 |
Why?
|
| Hyperglycemia | 1 | 2015 | 10 | 0.470 |
Why?
|
| Survival Analysis | 4 | 2018 | 11 | 0.460 |
Why?
|
| Area Under Curve | 3 | 2024 | 16 | 0.440 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2024 | 5 | 0.440 |
Why?
|
| Risk Assessment | 4 | 2016 | 44 | 0.440 |
Why?
|
| Cell Line | 3 | 2024 | 84 | 0.400 |
Why?
|
| Liposomes | 1 | 2013 | 24 | 0.390 |
Why?
|
| Body Fluids | 1 | 2013 | 4 | 0.390 |
Why?
|
| Protein Binding | 3 | 2019 | 115 | 0.390 |
Why?
|
| Organic Chemicals | 1 | 2012 | 3 | 0.390 |
Why?
|
| APACHE | 3 | 2021 | 3 | 0.390 |
Why?
|
| Microbial Viability | 1 | 2012 | 11 | 0.380 |
Why?
|
| Kidney Tubular Necrosis, Acute | 1 | 2012 | 1 | 0.370 |
Why?
|
| Biomarkers | 3 | 2018 | 81 | 0.370 |
Why?
|
| Drug Monitoring | 3 | 2020 | 10 | 0.360 |
Why?
|
| Cefazolin | 2 | 2024 | 2 | 0.350 |
Why?
|
| Intensive Care Units | 2 | 2024 | 17 | 0.350 |
Why?
|
| Risk Factors | 3 | 2019 | 159 | 0.350 |
Why?
|
| Larva | 2 | 2023 | 10 | 0.330 |
Why?
|
| Virulence | 2 | 2022 | 6 | 0.330 |
Why?
|
| Young Adult | 6 | 2016 | 787 | 0.320 |
Why?
|
| Doxycycline | 2 | 2022 | 3 | 0.320 |
Why?
|
| Staphylococcal Infections | 2 | 2024 | 7 | 0.320 |
Why?
|
| Serum | 3 | 2014 | 5 | 0.310 |
Why?
|
| Time Factors | 4 | 2014 | 163 | 0.310 |
Why?
|
| Cell Survival | 2 | 2024 | 54 | 0.300 |
Why?
|
| Prevalence | 3 | 2024 | 66 | 0.290 |
Why?
|
| Infusions, Intravenous | 4 | 2020 | 7 | 0.280 |
Why?
|
| Tetracyclines | 2 | 2017 | 15 | 0.260 |
Why?
|
| Injections, Subcutaneous | 2 | 2020 | 2 | 0.250 |
Why?
|
| Infant, Newborn | 3 | 2022 | 48 | 0.250 |
Why?
|
| Cross Infection | 2 | 2017 | 19 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 52 | 0.220 |
Why?
|
| Enterococcus faecalis | 2 | 2022 | 7 | 0.220 |
Why?
|
| United States | 2 | 2018 | 495 | 0.220 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2024 | 3 | 0.210 |
Why?
|
| Injections, Intravenous | 2 | 2015 | 6 | 0.210 |
Why?
|
| Computer Simulation | 2 | 2018 | 161 | 0.210 |
Why?
|
| Cohort Studies | 1 | 2024 | 115 | 0.210 |
Why?
|
| Metabolic Clearance Rate | 2 | 2015 | 5 | 0.210 |
Why?
|
| Models, Theoretical | 2 | 2016 | 75 | 0.210 |
Why?
|
| Reproducibility of Results | 3 | 2014 | 318 | 0.210 |
Why?
|
| Models, Animal | 1 | 2023 | 24 | 0.200 |
Why?
|
| Adolescent | 3 | 2016 | 758 | 0.200 |
Why?
|
| Half-Life | 1 | 2023 | 9 | 0.200 |
Why?
|
| Oxidative Stress | 1 | 2024 | 58 | 0.200 |
Why?
|
| Bacterial Load | 2 | 2013 | 8 | 0.200 |
Why?
|
| Iron Chelating Agents | 1 | 2023 | 1 | 0.200 |
Why?
|
| Body Weight | 2 | 2020 | 58 | 0.190 |
Why?
|
| Multilocus Sequence Typing | 1 | 2022 | 4 | 0.190 |
Why?
|
| Genomics | 1 | 2022 | 38 | 0.190 |
Why?
|
| Proteomics | 1 | 2022 | 19 | 0.180 |
Why?
|
| Oils, Volatile | 1 | 2022 | 3 | 0.180 |
Why?
|
| Phytochemicals | 1 | 2021 | 3 | 0.170 |
Why?
|
| Intestine, Small | 1 | 2021 | 6 | 0.170 |
Why?
|
| Phenols | 1 | 2021 | 13 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 2 | 2018 | 21 | 0.170 |
Why?
|
| Liver | 1 | 2021 | 49 | 0.170 |
Why?
|
| Comorbidity | 1 | 2021 | 47 | 0.170 |
Why?
|
| Nanoparticles | 1 | 2022 | 69 | 0.170 |
Why?
|
| Critical Illness | 1 | 2020 | 6 | 0.160 |
Why?
|
| Inflammation | 1 | 2020 | 57 | 0.150 |
Why?
|
| Piperacillin | 1 | 2019 | 3 | 0.150 |
Why?
|
| Incidence | 1 | 2019 | 30 | 0.150 |
Why?
|
| Infant, Premature | 2 | 2015 | 19 | 0.140 |
Why?
|
| Cytochrome b Group | 1 | 2018 | 1 | 0.140 |
Why?
|
| Lepidoptera | 1 | 2018 | 1 | 0.140 |
Why?
|
| Asia | 1 | 2018 | 1 | 0.140 |
Why?
|
| Glomerular Filtration Rate | 1 | 2018 | 4 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 5 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 2 | 0.140 |
Why?
|
| Gene Expression | 1 | 2018 | 49 | 0.130 |
Why?
|
| Tularemia | 1 | 2017 | 2 | 0.130 |
Why?
|
| Francisella tularensis | 1 | 2017 | 2 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2017 | 3 | 0.130 |
Why?
|
| Endocarditis | 1 | 2017 | 1 | 0.130 |
Why?
|
| Microdialysis | 1 | 2017 | 4 | 0.130 |
Why?
|
| Levofloxacin | 1 | 2017 | 3 | 0.130 |
Why?
|
| Phylogeny | 1 | 2017 | 59 | 0.130 |
Why?
|
| Thienamycins | 1 | 2017 | 6 | 0.130 |
Why?
|
| Maleates | 1 | 2017 | 1 | 0.130 |
Why?
|
| Kinetics | 1 | 2017 | 80 | 0.130 |
Why?
|
| Daptomycin | 2 | 2017 | 2 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 5 | 0.130 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 7 | 0.120 |
Why?
|
| Drug Costs | 1 | 2016 | 3 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2016 | 5 | 0.120 |
Why?
|
| Adenoviridae Infections | 1 | 2015 | 1 | 0.120 |
Why?
|
| Cystitis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Organophosphonates | 1 | 2015 | 1 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2015 | 26 | 0.120 |
Why?
|
| Cytosine | 1 | 2015 | 5 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2015 | 16 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 14 | 0.120 |
Why?
|
| Dopamine | 1 | 2015 | 26 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 19 | 0.110 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 4 | 0.110 |
Why?
|
| Arginine Vasopressin | 1 | 2014 | 2 | 0.110 |
Why?
|
| Risk | 1 | 2014 | 34 | 0.110 |
Why?
|
| Urine | 1 | 2014 | 4 | 0.110 |
Why?
|
| Biological Transport, Active | 1 | 2014 | 3 | 0.110 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 44 | 0.100 |
Why?
|
| Swine | 1 | 2014 | 50 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2013 | 3 | 0.100 |
Why?
|
| Respiratory Mucosa | 1 | 2013 | 5 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 7 | 0.100 |
Why?
|
| Uranyl Nitrate | 1 | 2012 | 1 | 0.100 |
Why?
|
| Biological Transport | 1 | 2012 | 18 | 0.090 |
Why?
|
| Drug Dosage Calculations | 1 | 2012 | 1 | 0.090 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2012 | 4 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2012 | 6 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 11 | 0.090 |
Why?
|
| Dogs | 1 | 2012 | 15 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 5 | 0.090 |
Why?
|
| Membranes, Artificial | 1 | 2012 | 9 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 47 | 0.090 |
Why?
|
| Colombia | 1 | 2024 | 1 | 0.060 |
Why?
|
| Nose | 1 | 2024 | 4 | 0.050 |
Why?
|
| Whole Genome Sequencing | 1 | 2024 | 12 | 0.050 |
Why?
|
| Monobactams | 1 | 2023 | 1 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 17 | 0.050 |
Why?
|
| Emulsions | 1 | 2022 | 2 | 0.050 |
Why?
|
| Solubility | 1 | 2022 | 10 | 0.050 |
Why?
|
| Particle Size | 1 | 2022 | 41 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2022 | 26 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2021 | 33 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2021 | 31 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2019 | 1 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2017 | 3 | 0.030 |
Why?
|
| Methicillin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Nafcillin | 1 | 2017 | 1 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 2017 | 1 | 0.030 |
Why?
|
| Gentamicins | 1 | 2017 | 3 | 0.030 |
Why?
|
| Ampicillin | 1 | 2017 | 2 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2016 | 9 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2015 | 1 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2015 | 7 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2014 | 1 | 0.030 |
Why?
|
| Italy | 1 | 2014 | 6 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 14 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 17 | 0.030 |
Why?
|
| Inpatients | 1 | 2014 | 31 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 12 | 0.030 |
Why?
|
| Limit of Detection | 1 | 2014 | 27 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 3 | 0.030 |
Why?
|
| Infant | 1 | 2014 | 78 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 67 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2014 | 180 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 126 | 0.020 |
Why?
|
| Vancomycin Resistance | 1 | 2012 | 1 | 0.020 |
Why?
|
| Patient Care Team | 1 | 2012 | 3 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2012 | 3 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 38 | 0.020 |
Why?
|